Press Releases

PharmaResearch Products Ltd use call option in Promore Pharma

Promore Pharma AB (publ) Interim report January – September 2018

Promore Pharma receives approval for Phase III study with PXL01 in India

Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma

Promore Pharma has had a successful meeting with the FDA regarding PXL01

Promore Pharma has enrolled first patient in HEAL LL-37 in Poland

Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland

Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring

Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

Interim report January – June 2018

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018

Promore Pharma receives approval for Phase IIb trial with LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018

Promore Pharma AB (publ) Interim report January – March 2018

Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018

Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd

Promore Pharma 2017 Annual report published

Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma Regains Rights for PXL01 Manufacturing

Year-end report 2017

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma Adjusts Plans for PXL01 in North America